The frequent activation of PI3K, and its downstream effectors, has prompted multiple independent efforts to develop selective inhibitors against the PI3K pathway as a chemotherapeutic strategy in cancer, and a number of these compounds are now in clinical development [2]. The gene discussed is PIK3CA; the disease is cancer.